adenosine diphosphate has been researched along with Epithelial Ovarian Cancer in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 9 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, YJ; Choi, JJ; Choi, JY; Hwang, JR; Jeong, SY; Lee, JW; Ryu, JY; Sa, JK; Shim, JI | 1 |
| Arenare, L; Baldassarre, G; Bartoletti, M; Califano, D; Capoluongo, E; Chiodini, P; Costi, MP; D'Incalci, M; Greggi, S; Marchini, S; Mezzanzanica, D; Musacchio, L; Normanno, N; Perrone, F; Pignata, S; Scala, S; Schettino, C | 1 |
| Aryal, N; Asher, R; Berton, D; Colombo, N; Freimund, AE; Frenel, JS; Huzarski, T; Kim, JW; Korach, J; Ledermann, JA; Lee, CK; Oza, AM; Park-Simon, TW; Pautier, P; Penson, RT; Pignata, S; Pujade-Lauraine, E; Sonke, GS; Tamura, K; Vidal, L | 1 |
| Bernard, J; Douville, P; Gregoire, J; Langlais, EL; Mehros, W; Plante, M; Renaud, MC; Sebastianelli, A | 1 |
| Lu, W; Shen, Y; Shen, Z; Tang, S; Wei, X; Xu, J | 1 |
| Arend, R; Ethier, JL; Fuh, KC; Kohn, EC; Konecny, GE; Konstantinopoulos, PA; Odunsi, K; Swisher, EM; Zamarin, D | 1 |
| Compton, K; Karsan, A; Kwon, JS; Santos, J; Schrader, KA; Sun, S; Tinker, AV | 1 |
| Bose, S; Huang, Q; Kontos, CD; Previs, RA; Shen, X; Whitaker, R; Yao, H | 1 |
| Cheng, H; Liu, H; Xiang, Y; Yang, J | 1 |
1 review(s) available for adenosine diphosphate and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.
Topics: Adenosine Diphosphate; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Ribose; Treatment Outcome | 2021 |
1 trial(s) available for adenosine diphosphate and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Topics: Adenosine Diphosphate; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Disease Progression; Female; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Ribose | 2022 |
7 other study(ies) available for adenosine diphosphate and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
Topics: Adenosine Diphosphate; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; DNA; Female; Humans; Ovarian Neoplasms; Phthalazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Ribose; Xenograft Model Antitumor Assays | 2022 |
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
Topics: Adenosine Diphosphate; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Mangifera; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Ribose | 2022 |
Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a Diagnosis of Epithelial Tubo-Ovarian Carcinoma.
Topics: Adenosine Diphosphate; BRCA1 Protein; BRCA2 Protein; Canada; Carcinoma; Carcinoma, Ovarian Epithelial; Female; Genes, BRCA2; Genetic Predisposition to Disease; Germ Cells; Germ-Line Mutation; Humans; Mismatch Repair Endonuclease PMS2; Mutation; Ovarian Neoplasms; Peritoneal Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Retrospective Studies; Ribose | 2022 |
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer.
Topics: Adenosine Diphosphate; AMP-Activated Protein Kinases; Animals; Apoptosis; Arsenic Trioxide; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Ferroptosis; Humans; Mice; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Ribose; Stearoyl-CoA Desaturase | 2022 |
State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report.
Topics: Adenosine Diphosphate; Antineoplastic Agents; Biomarkers; Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Female; Humans; National Cancer Institute (U.S.); Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Ribose; Tumor Microenvironment; United States | 2022 |
Germline Testing and Somatic Tumor Testing for
Topics: Adenosine Diphosphate; Aged; Antineoplastic Agents; BRCA1 Protein; Carcinoma, Ovarian Epithelial; Female; Germ Cells; Germ-Line Mutation; Humans; Medicare; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Ribose; United States | 2022 |
Using genetically encoded fluorescent biosensors to interrogate ovarian cancer metabolism.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Biosensing Techniques; Carboplatin; Carcinoma, Ovarian Epithelial; Culture Media, Conditioned; Female; Humans; NAD; NADP; Ovarian Neoplasms; Tumor Microenvironment | 2022 |